Partnership website: https://www.eppermed.eu/
The European Partnership for Personalised Medicine (EP PerMed) aims to align and promote regional and national priority setting and funding for research and implementation projects in the field of personalised medicine among the EU Member States, regions and beyond.
EP PerMed builds on over 15 years of EU-funded consortia, initiatives & events, but also on a wide range of national & European regional activities and efforts in all areas of the personalised medicine value continuum.
Grant Agreement negotiations for EP PerMed are ongoing. It is expected that the following Flemish partner organisations to participate in the Partnership:
Belgium (Flanders) | Government of Flanders – Vlaams Gewest | https://www.vlaanderen.be/ |
Belgium (Flanders) | Research Foundation – Flanders – Fonds Wetenschappelijk Onderzoek | https://www.fwo.be/en/ |
Belgium (Flanders) | Flanders innovation & entrepreneurship – Fonds voor Innoveren en Ondernemen | https://www.vlaio.be/en |
Results will translate into delivery of better prevention and healthcare services, improved health outcomes for patients and citizens, and increased satisfaction with health systems.
Open & closed calls
A first joint transnational call for proposals under EP PerMed on "Identification or Validation of Targets for Personalised Medicine Approaches (PMTargets)" was launched in January 2024. The deadline for pre-proposals has passed. The result of the call for proposals is not expected before October 2024. First projects are expected to start end of 2024, beginning of 2025.
Information pages for stakeholders in Flanders:
- dedicated VLAIO webpage
- dedicated FWO webpage
You can register to EP PerMed's newsletter to be kept informed about future calls for proposals here.
Within EP PerMed, several earlier European Initiatives are joined under one roof. It will continue the activities of ERA PerMed in funding transnational innovation and research projects. In addition, EP PerMed will closely together with the International Consortium for Personalised Medicine ICPerMed for overarching strategic activities.
'ICPerMed Family' of Coordination and Support Actions:
Commission services: RTD-EP-PERSONALISED-MEDICINE@ec.europa.eu
The Partnership: eppermed@dlr.de
Partnerships group the EC and private and/or public partners, to coordinate and streamline the research & innovation initiatives and funding in some selected key domains.
ChemStream is an innovative chemical R&D company, specialized in translating material problems in sustainable formulations with focus on nano-dispersions, functional coatings and inkjet inks. Within LORCENIS they will develop super absorbing polymers (SAPs) to be mixed within the concrete matrices for improving the active internal curing, self-healing and self-sealing properties of the concrete. Grindig SAPs.
ChemStream bvba and Ghent University are involved in Horizon 2020-project for developing long lasting reinforced concrete for energy infrastructures.